Management of patients with intermittent claudication.
Intermittent claudication, the most common symptomatology of peripheral arterial disease, is characterised by lower-extremity discomfort induced by exercise and relieved by rest. The most serious potential outcome of the condition is increased morbidity and mortality from cardiovascular disease, with which it is often associated, thus prompt diagnosis and management are crucial. Therapy consists of structured exercise and reduction of cardiovascular risk factors, followed by or together with pharmacological interventions with anticlaudicants (cilostazol or pentoxifylline) and specific antiplatelet agents (aspirin, clopidogrel). Revascularisation procedures are indicated in those with limb-threatening or lifestyle disabling disease.
Olin
J W
JW
Vascular Medicine Programme, Mount Sinai School of Medicine, The Zena and Michael A Wiener Cardiovascular Institute, New York, NY 10029-6574, USA.
D001241:Aspirin / Q000627:therapeutic use; D001807:Blood Vessel Prosthesis; D000077407:Cilostazol; D000077144:Clopidogrel; D005081:Exercise Therapy / Q000379:methods; D006801:Humans; D007383:Intermittent Claudication / Q000175:diagnosis / Q000628:therapy*; D008487:Medical History Taking; D010431:Pentoxifylline / Q000627:therapeutic use; D010808:Physical Examination; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013777:Tetrazoles / Q000627:therapeutic use; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine; D001241:Aspirin; D010431:Pentoxifylline